Han Gang, Han Yun, Yu Lingyan, Zhao Yuhua, Yu Zhenwei
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China.
Research Center for Clinical Pharmacy, Zhejiang University, Hangzhou 310058, China.
Healthcare (Basel). 2023 Mar 6;11(5):764. doi: 10.3390/healthcare11050764.
The aim of this study was to assess the patterns and trends of pharmacological treatment for outpatients with postherpetic neuralgia (PHN) in China in the period 2015-2019. Prescription data for outpatients with PHN were extracted from the database of the Hospital Prescription Analysis Program of China according to the inclusion criteria. The trends in yearly prescriptions and corresponding costs were analyzed and stratified by drug class and specific drugs. A total of 19,196 prescriptions from 49 hospitals in 6 major regions of China were included for analysis. The yearly prescriptions increased from 2534 in 2015 to 5676 in 2019 ( = 0.027), and the corresponding expenditures increased from CNY 898,618 in 2015 to CNY 2,466,238 in 2019 ( = 0.027). Gabapentin and pregabalin are the most commonly used drugs for PHN, and more than 30% of these two drugs were combined with mecobalamin. Opioids were the second most frequently prescribed drug class, and oxycodone accounted for the largest share of the cost. Topical drugs and TCAs are rarely used. The frequent use of pregabalin and gabapentin was in accordance with current guidelines; however, the use of oxycodone raised concerns about rationality and economic burden. The results of this study may benefit the allocation of medical resources and management for PHN in China and other countries.
本研究旨在评估2015 - 2019年期间中国门诊带状疱疹后神经痛(PHN)患者的药物治疗模式和趋势。根据纳入标准,从中国医院处方分析项目数据库中提取PHN门诊患者的处方数据。按药物类别和具体药物对年度处方趋势及相应费用进行分析和分层。共纳入中国6个主要地区49家医院的19196张处方进行分析。年度处方量从2015年的2534张增加到2019年的5676张( = 0.027),相应支出从2015年的898618元人民币增加到2019年的2466238元人民币( = 0.027)。加巴喷丁和普瑞巴林是治疗PHN最常用的药物,这两种药物中有超过30%与甲钴胺联合使用。阿片类药物是第二常用的药物类别,羟考酮占费用的最大份额。局部用药和三环类抗抑郁药很少使用。普瑞巴林和加巴喷丁的频繁使用符合当前指南;然而,羟考酮的使用引发了对合理性和经济负担的担忧。本研究结果可能有助于中国及其他国家PHN医疗资源的分配和管理。